UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000037071
Receipt No. R000042243
Scientific Title A study for measurement of Glycemic Index (GI) of two kinds of foods in adult males and females
Date of disclosure of the study information 2019/06/14
Last modified on 2020/02/28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A study for measurement of Glycemic Index (GI) of two kinds of foods in adult males and females
Acronym A study for measurement of Glycemic Index (GI) of two kinds of foods
Scientific Title A study for measurement of Glycemic Index (GI) of two kinds of foods in adult males and females
Scientific Title:Acronym A study for measurement of Glycemic Index (GI) of two kinds of foods
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Measure the GI values of two kinds of test foods
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Glycemic Index
Key secondary outcomes Maximum blood glucose level (Cmax)
Amount of change in blood glucose levels based on the blood glucose level before loading, Incremental area under the blood glucose response curve (IAUC), Area under the curve(AUC)
Amount of change in insulin levels based on the insulin level before loading, Incremental area under the insulin response curve (IAUC), Area under the curve(AUC)
Amount of change in questionnaire on Appetite(VAS-questionnaire) based on the appetite(VAS-questionnaire) before loading

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Intake of a reference food (single ingestion) - washout period - a test food 1(single ingestion) - washout period - a test food 2(single ingestion)
Interventions/Control_2 Intake of a reference food(single ingestion) - washout period - a test food 2 (single ingestion) - washout period - a test food 1(single ingestion)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
50 years-old >=
Gender Male and Female
Key inclusion criteria (1) Healthy males and females aged between 20 and 50
(2) Subjects who have a difference within 25% in the incremental area under the curve (IAUC) of two preliminary tests
(3) Women have a stable menstrual cycle
(4) Subjects with blood glucose level greater than 70 mg /dL or more and 110 mg /dL or less in glucometer
Key exclusion criteria (1) Subjects routinely taking medicine or health food which may influence glucose metabolism
(2) Subjects whose BMI exceeds 30.0 kg/m2
(3) Subjects whose blood glucose level exceeds 126 mg/dL
(4) Subjects who have been pointed out as impaired glucose tolerance within 1 year
(5) Subjects who are suspected as impaired glucose tolerance in preliminary examination
(6) Subjects whose blood glucose level exceeds 110 mg/dL in glucometer on admission
(7) Subjects planned to travel abroad during the study period
(8) Subjects having possibilities for emerging allergy related to the current study
(9) Subjects who drink much alcohol
(10) Subjects who do excessive smoking
(11) Subjects who donated blood (blood donation etc.) exceeding 200 mL within 1 month or
400 mL within 4 months
(12) Subjects who have under treatment or a history of serious disease(e.g., diabetes, liver disease, kidney disease, or heart disease)
(13) Subjects who have under treatment (e.g.,adiposity,hyperlipidemia, hypertension) that affects the evaluation of this study or medical history of serious illness for medication
(14) Subjects whose values of physical measurement, physical examination and clinical laboratory are significantly different from the reference range
(15) Subjects who may be pregnant or are pregnant, breastfeeding, or those who desire pregnancy during the study period
(16) Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies
(17) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
(18) Subjects who are judged as ineligible by the clinical investigator
Target sample size 12

Research contact person
Name of lead principal investigator
1st name Fumitoshi
Middle name
Last name Horie
Organization Aisei Hospital Ueno Clinic
Division name Director, Surgical
Zip code 110-0015
Address 2-18-6, Higashiueno, Taitou-ku, Tokyo
TEL 03-3834-3518
Email cl-rece@aisei-byouin.or.jp

Public contact
Name of contact person
1st name Kunihiko
Middle name
Last name Wasaki
Organization TTC Co., Ltd.
Division name Clinical Research Planning Department
Zip code 150-0021
Address Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo
TEL 03-5459-5329
Homepage URL
Email k.wasaki@ttc-tokyo.co.jp

Sponsor
Institute TTC Co., Ltd.
Institute
Department

Funding Source
Organization Mizkan Holdings Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Aisei Hospital Ueno Clinic Research Ethics Committee
Address 2-18-6, Higashiueno, Taitou-ku, Tokyo
Tel 03-6455-0880
Email t.saito@ttc-smo.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 06 Month 14 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 06 Month 13 Day
Date of IRB
2019 Year 06 Month 13 Day
Anticipated trial start date
2019 Year 06 Month 15 Day
Last follow-up date
2019 Year 09 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 06 Month 14 Day
Last modified on
2020 Year 02 Month 28 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042243

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.